Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05422534 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

CoQ10 and Exercise for Mitochondrial Dysfunction in Advance Kidney Disease

StatusRecruiting
PhasePhase 3
Started2023-06-01
View on ClinicalTrials.gov ↗

Amendment history

2025-12-30
minor
3 amendments v5-v7
3 re-verifications since 2024-08-06, no change to tracked fields
2023-07-27
notable
Not Yet Recruiting→Recruiting Study Status, Contacts/Locations v4
Trial statusNot Yet Recruiting→Recruiting
Start dateestimated 2023-05-20→confirmed 2023-06-01
Study sites1→2
2023-04-26
minor
Study Status v3
Primary completion date2027-03-20→2027-06-20
Start date2023-03-20→2023-05-20
2023-02-27
minor
Study Identification, Study Status v2
Start date2023-01-20→2023-03-20
2022-10-11
minor
Study Status v1
Start date2022-08-20→2023-01-20
2022-06-13
minor
Original filing
Frailty and sarcopenia are modifiable risk factors for morbidity and mortality in patients with ESRD. Exercise is the recommended intervention to prevent frailty and sarcopenia, however, many clinical trials have shown limited clinical improvement in muscle mass and physical function. We propose that mitochondrial dysfunction is one of the deterrents to the effectiveness of the exercise. We plan to evaluate the additive effect of HIIT and CoQ10, a mitochondrial-targeted therapy, on mitochondrial function and physical performance. Understanding the interplay among CoQ10, exercise, and mitochondrial function will identify novel mechanisms to improve the efficiency of exercise. This will also serve to prevent frailty, sarcopenia, and muscle dysfunction in patients with ESRD.
Trial Details
NCT Number NCT05422534
Lead Sponsor Vanderbilt University Medical Center
Collaborators: University of California, Davis
Conditions End Stage Renal Disease
Enrollment 156 participants
Start Date 2023-06-01
Primary Completion 2027-06-20 (estimated)
Study Completion 2027-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-01-02